Biosimilar Denied: Hospira's Retacrit Could Head Back To FDA In First Half 2016

Breaking cone of silence around 351(k) applications with passed user fee dates, Hospira parent Pfizer says additional clinical trials not needed following complete response letter for epoetin alfa biosimilar.